{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:09:00Z","timestamp":1781258940003,"version":"3.54.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to methotrexate (MTX) from a 52-week randomised controlled parent study (PS) and long-term extension (LTE) through June 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The PS (NCT02889796) randomised MTX-IR patients to filgotinib 200 (FIL200) or 100\u2009mg (FIL100), adalimumab (ADA) 40\u2009mg, or placebo; all took stable background MTX. At week (W) 24, placebo patients were rerandomised to FIL200 or FIL100. The primary endpoint was W12 American College of Rheumatology 20% improvement; safety was assessed by adverse event (AE) reporting. For the LTE (NCT03025308), eligible filgotinib patients continued FIL200\/FIL100; ADA patients were rerandomised (blinded) to FIL200 or FIL100; all continued MTX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In all, 114\/147 Japanese patients completed the PS, 115 enrolled in LTE, and 103 remained on study in June 2020. In the PS, AEs were consistent with the overall population, and W24 efficacy was maintained or improved through W52, comparable with the overall population. LTE AE incidences were similar between doses; filgotinib efficacy was consistent from baseline to W48 and similar between PS ADA and filgotinib patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among MTX-IR Japanese patients, filgotinib maintained efficacy over 1\u2009year; LTE safety was consistent with the PS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac084","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T08:28:56Z","timestamp":1659515336000},"page":"668-679","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Matsubara Mayflower Hospital , Kato, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University , Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University , Hidaka, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Aichi Developmental Disability Center , Kasugai, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine , Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard G","family":"Combe","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Montpellier, Montpellier University , Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research , Duncansville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang University Institute of Bioscience and Biotechnology , Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C","family":"Keystone","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"Griffith University of Queensland , Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Genovese","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Matzkies","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Pechonkina","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[{"name":"Gilead Sciences K.K. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gong","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, and Saitama Medical University , Iruma, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"2023070502120614100_R1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2023070502120614100_R2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2023070502120614100_R3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/14397595.2013.854059","article-title":"Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)","volume":"24","author":"Yamanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023070502120614100_R4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023070502120614100_R5","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2023070502120614100_R6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070502120614100_R7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070502120614100_R8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023070502120614100_R9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2023070502120614100_R10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023070502120614100_R11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120614100_R12","article-title":"Summary of product characteristics","year":"2020"},{"key":"2023070502120614100_R13","article-title":"Japanese package insert","year":"2020"},{"key":"2023070502120614100_R14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/mr\/roab021","article-title":"Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)","volume":"32","author":"Atsumi","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120614100_R15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14397595.2020.1859675","article-title":"Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: subgroup analyses of a global phase 3 study (FINCH 2)","volume":"32","author":"Takeuchi","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120614100_R16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/mr\/roab030","article-title":"Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120614100_R17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2023070502120614100_R18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2023070502120614100_R19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2023070502120614100_R20","first-page":"789","article-title":"The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2023070502120614100_R21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2023070502120614100_R22","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2023070502120614100_R23","article-title":"Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults with Rheumatoid Arthritis (FINCH 4)","author":"United States Library of Medicine","year":"2021"},{"key":"2023070502120614100_R24","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.276","article-title":"Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH 1 52-week results","volume-title":"EULAR2020","author":"Combe"},{"key":"2023070502120614100_R25","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac132.029","article-title":"Clinical outcomes up to week 48 of filgotinib treatment in an ongoing long-term extension trial of RA patients with inadequate response to MTX initially treated with filgotinib or adalimumab during the phase 3 parent trial","volume-title":"ACR2021","author":"Combe"},{"key":"2023070502120614100_R26","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243217","article-title":"Varicella caused by airborne transmission of a localised herpes zoster infection in a family","volume":"14","author":"Hatsushika","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2023070502120614100_R27","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1080\/21645515.2021.1953346","article-title":"Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice","volume":"17","author":"Stadtmauer","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2023070502120614100_R28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3899\/jrheum.161196","article-title":"Association between medications and herpes zoster in Japanese patients with rheumatoid arthritis: a 5-year prospective cohort study","volume":"44","author":"Harada","year":"2017","journal-title":"J Rheumatol"},{"key":"2023070502120614100_R29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"key":"2023070502120614100_R30","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023070502120614100_R31","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00296-010-1524-0","article-title":"Incidence of malignancy in Japanese patients with rheumatoid arthritis","volume":"31","author":"Yamada","year":"2011","journal-title":"Rheumatol Int"},{"key":"2023070502120614100_R32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2023070502120614100_R33","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2800-6","article-title":"Risk for cardiovascular disease in Japanese patients with rheumatoid arthritis: a large-scale epidemiological study using a healthcare database","volume":"5","author":"Tanaka","year":"2016","journal-title":"Springerplus"},{"key":"2023070502120614100_R34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40744-018-0113-7","article-title":"Long-term radiographic and patient-reported outcomes in patients with rheumatoid arthritis treated with tofacitinib: ORAL start and ORAL scan post-hoc analyses","volume":"5","author":"Strand","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2023070502120614100_R35","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s10067-018-4221-0","article-title":"Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study","volume":"37","author":"van der Heijde","year":"2018","journal-title":"Clin Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac084\/45612285\/roac084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/668\/50797274\/roac084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/668\/50797274\/roac084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:04:28Z","timestamp":1688526268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/4\/668\/6653672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,4]]},"published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac084","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,8,4]]}}}